Results For "Aliada's-lead-investigational-asset-is-ALIA-1758"

No record found.

Upcoming E-conference

July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zealand Pharma’s petrelintide delivers double-digit weight loss in next-gen obesity treatment

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India

Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging